Equities

Y-mAbs Therapeutics Inc

YMAB:NSQ

Y-mAbs Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.95
  • Today's Change-0.05 / -0.36%
  • Shares traded74.99k
  • 1 Year change+168.79%
  • Beta0.7023
Data delayed at least 15 minutes, as of Sep 20 2024 16:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform6
Hold1
Sell1
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Y-mAbs Therapeutics Inc have a median target of 21.50, with a high estimate of 26.00 and a low estimate of 11.00. The median estimate represents a 53.57% increase from the last price of 14.00.
High85.7%26.00
Med53.6%21.50
Low-21.4%11.00

Earnings history & estimates in USD

On Aug 12, 2024, Y-mAbs Therapeutics Inc reported 2nd quarter 2024 losses of -0.21 per share.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate-157.42%
Y-mAbs Therapeutics Inc reported annual 2023 losses of -0.49 per share on Feb 29, 2024.
Average growth rate+8.58%
More ▼

Revenue history & estimates in USD

Y-mAbs Therapeutics, Inc. had 2nd quarter 2024 revenues of 22.80m. This missed the 23.02m consensus estimate of the 6 analysts following the company. This was 12.58% above the prior year's 2nd quarter results.
Average growth rate+3.12%
Y-mAbs Therapeutics, Inc. had revenues for the full year 2023 of 84.82m. This was 29.96% above the prior year's results.
Average growth rate+61.72%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.